MAD2L1 Polyclonal antibody

• Featured Product
• KD/KO Validated

MAD2L1 Polyclonal Antibody for IF, IHC, IP, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IP, IHC, IF,ELISA

Conjugate

Unconjugated

Publications

13

Cat no : 10337-1-AP

Synonyms

HSMAD2, MAD2, MAD2 like protein 1, MAD2L1

---

Validation Data Gallery

• 

  WB analysis using 10337-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10337-1-AP (MAD2L1 antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human liver cancer using 10337-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer using 10337-1-AP (MAD2L1 antibody) at dilution of 1:50 (under 25x lens).

• 

  WB analysis of HEK-293 using 10337-1-AP

  WB result of MAD2L1 antibody (10337-1-AP, 1:500) with si-control and si-MAD2L1 transfected HEK293 cells.

• 

  IP experiment of HEK-293 using 10337-1-AP

  IP Result of anti-MAD2L1 (IP:10337-1-AP, 3ug; Detection:10337-1-AP 1:500) with HEK-293 cells lysate 1800ug.

• 

  IF Staining of HEK-293 using 10337-1-AP

  Immunofluorescent analysis of (4% PFA) fixed HEK-293 cells using 10337-1-AP (MAD2L1 antibody) at dilution of 1:50 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

---

Tested Applications

• Positive WB detected in: Daudi cells, HeLa cells, HEK-293 cells, rat liver tissue
• Positive IP detected in: HEK-293 cells
• Positive IHC detected in: human liver cancer tissue, human ovary tumor tissue; Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
• Positive IF detected in: HEK-293 cells

Recommended dilution

• Western Blot (WB): WB : 1:500-1:1000
• Immunoprecipitation (IP): IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB
• Immunohistochemistry (IHC): IHC : 1:20-1:200
• Immunofluorescence (IF): IF : 1:50-1:500

Sample-dependent, check data in validation data gallery

Published Applications

• WB: See 8 publications below
• IHC: See 4 publications below
• IF: See 1 publications below

Product Information

10337-1-AP targets MAD2L1 in WB, IP, IHC, IF,ELISA applications and shows reactivity with human, mouse, rat samples.

• Tested Reactivity: human, mouse, rat
• Cited Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: MAD2L1 fusion protein Ag0307
• Full Name: MAD2 mitotic arrest deficient-like 1 (yeast)
• Calculated molecular weight: 24 kDa
• Observed molecular weight: 25-30 kDa
• GenBank accession number: BC000356
• Gene symbol: MAD2L1
• Gene ID (NCBI): 4085
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

MAD2 mitotic arrest deficient-like 1 (yeast) (MAD2L1, synonyms: MAD2, HSMAD2) is a component of the mitotic spindle assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate. MAD2L1 is localized to human chromosome band 5q23.3 by in situ hybridization.

Publications

Species	Application	Title
human	WB	Biometals; Probing the cell death signaling pathway of HepG2 cell line induced by copper-1,10-phenanthroline complex.; Authors - Jieyuan Wu
human	WB	Oncogene; KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells.; Authors - Zhi-Chuan Zhu
mouse	WB	Sci Adv; The cohesin release factor Wapl interacts with Bub3 to govern SAC activity in female meiosis I.; Authors - Changyin Zhou
human	WB	Int J Mol Sci; Identification of Overexpressed Genes in Malignant Pleural Mesothelioma.; Authors - Federica Morani
human	IHC	Oncol Lett; Mitotic arrest deficiency 2 induces carcinogenesis in mucinous ovarian tumors.; Authors - Nakano Yusuke Y
human	IHC	Exp Ther Med; Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.; Authors - Morishita Masanari M